Get Premium to unlock powerful stock data
NYSE:MYOV (UK)  
Myovant Sciences Ltd logo

Myovant Sciences Ltd

$ 12.96 +0.53 (+4.26%) 08:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 1.24B
Enterprise V:
$ 1.17B
Volume:
392.04K
Avg Vol (2M):
850.20K
Also Trade In:
Volume:
392.04K
Market Cap $:
1.24B
PE Ratio:
At Loss
Avg Vol (2-Month):
850.20K
Enterprise Value $:
1.17B
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Myovant Sciences Ltd
NAICS : 541714 SIC : 2834
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Description
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Name Current Vs Industry Vs History
Cash-To-Debt 1.18
Equity-to-Asset -0.91
Debt-to-Equity -0.78
Debt-to-EBITDA -2
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.82
Distress
Grey
Safe
Beneish M-Score 2.61
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 20.5
3-Year EPS without NRI Growth Rate 18.4
3-Year FCF Growth Rate 4.9
Name Current Vs Industry Vs History
5-Day RSI 58.87
9-Day RSI 59.14
14-Day RSI 58.2
6-1 Month Momentum % -33.98
12-1 Month Momentum % -54.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.95
Quick Ratio 1.92
Cash Ratio 1.73
Days Inventory 38.58
Days Sales Outstanding 22.37
Days Payable 84.9

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.6
Name Current Vs Industry Vs History
Gross Margin % 77.68
Operating Margin % -81.11
Net Margin % -89.18
ROA % -31.62
ROIC % -80.81
ROC (Joel Greenblatt) % -1569.29
ROCE % -49.72

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 5.22
EV-to-EBIT -6.25
EV-to-EBITDA -6.36
EV-to-Revenue 5.06
EV-to-FCF -4.35
Earnings Yield (Greenblatt) % -16

Financials (Next Earnings Date:2022-07-28 Est.)

MYOV's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NYSE:MYOV

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 230.972
EPS (TTM) ($) -2.21
Beta 3.25
Volatility % 53.58
14-Day RSI 58.2
14-Day ATR ($) 0.849659
20-Day SMA ($) 12.1355
12-1 Month Momentum % -54.87
52-Week Range ($) 7.67 - 27.43
Shares Outstanding (Mil) 95.33

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Myovant Sciences Ltd Filings

Document Form Filing Date
No Filing Data

Headlines

See More